NDA/BLA dossier lifecycle — filing acceptance, parallel discipline review, information requests, and the PDUFA approval decision
Modern drug applications are submitted in the ICH Common Technical Document (CTD) format, a harmonized five-module structure recognized by FDA, EMA, and other major regulators — a standardization achievement that lets sponsors reuse the bulk of a single global dossier across multiple jurisdictions rather than building entirely separate submissions.
Module 1 is region-specific administrative and prescribing information (not harmonized — each regulator has its own Module 1 requirements). Module 2 provides high-level written and tabulated summaries of quality, nonclinical, and clinical data — often the first thing reviewers read and disproportionately influential in shaping first impressions. Module 3 is the full Chemistry, Manufacturing, and Controls (CMC) package: drug substance and drug product specifications, manufacturing process description, stability data, analytical methods. Module 4 contains complete nonclinical study reports (pharmacology, pharmacokinetics, toxicology). Module 5 contains full clinical study reports for every trial supporting the application, including raw patient-level datasets in standardized formats (SDTM/ADaM).
A pre-submission meeting (Type B meeting for a novel product's pre-NDA/BLA discussion) is where sponsors align with FDA on what data package will be considered adequate — skipping this step or ignoring FDA feedback from it is one of the most common reasons a subsequently filed application encounters late-stage surprises during review.
Before any reviewer evaluates whether a drug actually works or is safe, the application must pass a purely administrative filing review — FDA has 60 calendar days from receipt to decide whether the submission is complete enough to review at all, a decision made on structural completeness, not scientific merit.
A Refuse-to-File (RTF) decision is not a judgment that the drug is unsafe or ineffective — it means the application as submitted lacks required structural elements (a missing required study report, an incomplete CMC section, a stability program that doesn't cover the requested shelf life) needed to even begin substantive review. An RTF is procedurally expensive: the sponsor must address the deficiency and resubmit, and the 60-day filing clock (and the entire subsequent review clock) restarts from the resubmission date.
Because an RTF costs months of delay for what is often a fixable administrative gap, well-resourced sponsors invest heavily in pre-submission meetings and internal "mock filing review" audits specifically to avoid this fate — the filing review, despite being purely administrative, is one of the highest-leverage moments in the entire regulatory timeline precisely because failing it is so schedule-costly relative to how mechanical the underlying check actually is.
Once filed, the application does not move through a single linear review queue — it is split among independent discipline-specific review teams that work in parallel, each with authority to raise questions, request data, and ultimately sign off (or not) on their portion of the safety/efficacy/quality case.
Running discipline reviews in parallel rather than sequentially is what makes a 10-month standard review timeline achievable at all for a dossier this large — the CMC team evaluates manufacturing and quality data completely independently of whether the clinical team is satisfied with efficacy evidence, and both proceed independently of the nonclinical toxicology review.
The tradeoff is coordination risk: because teams work independently, a late-emerging CMC facility inspection finding can derail an otherwise clean clinical review, or a statistical reviewer's reanalysis of a pivotal trial's primary endpoint can undercut a clinical team's initially favorable read — final approval requires every discipline track to reach a satisfactory conclusion, so review speed is effectively bottlenecked by whichever track is slowest or most problematic, not by the average pace across tracks.
Review is rarely a silent, one-way process — reviewers routinely issue Information Requests (IRs) mid-cycle asking for clarification, additional analyses, or missing data, which sponsors are expected to answer quickly to avoid delaying the review clock; unresolved major issues at the action date trigger a Complete Response Letter rather than approval.
A Complete Response Letter (CRL) formally communicates that FDA cannot approve the application in its current form and specifies the deficiencies that must be resolved — grounds range from efficacy concerns (a pivotal trial not meeting its endpoint robustly enough) to safety signals requiring further characterization, to Chemistry-Manufacturing-Controls issues (a facility inspection finding, a stability data gap), and increasingly, manufacturing facility inspection outcomes have become one of the most common and hardest-to-predict CRL triggers, since they depend on real-time inspection logistics largely outside the sponsor's direct control at the moment of the PDUFA date.
A CRL is not necessarily a final rejection: many drugs are eventually approved after a CRL response addresses the cited deficiencies, classified as either a Class 1 resubmission (minor, typically CMC or labeling issues, 2-month review) or Class 2 resubmission (more substantial, potentially requiring new data, 6-month review) — but every CRL cycle costs the sponsor months to years of delay and, for a publicly traded company, is often a significant negative catalyst regardless of the ultimate outcome.
The gap between "first-cycle approval" and "eventual approval after CRL" is a critical distinction in regulatory strategy — many blockbuster drugs received a CRL on their first review cycle and were approved 6–18 months later after addressing the cited deficiencies, so a CRL should be read as a specific, addressable gap rather than a verdict on the drug itself.
The regulatory pathway a sponsor pursues sets the statutory review clock and shapes how much early, iterative engagement with FDA is available before formal submission — but it is important to separate what these designations actually speed up from what they do not.
Priority Review shortens the formal review clock itself (10 months → 6 months) and is granted when the drug, if approved, would offer significant improvement in safety or effectiveness over existing therapy for a serious condition — this is a pure timeline accelerator granted at the point of filing.
Breakthrough Therapy designation, by contrast, does not shorten the formal review clock at all — its value is earlier and more intensive FDA engagement during development (more frequent meetings, rolling review of completed sections, organizational commitment of senior FDA staff) intended to compress the overall time to submission by resolving development-stage uncertainties faster, not the review itself.
Accelerated Approval allows approval based on a surrogate endpoint reasonably likely to predict clinical benefit (e.g., tumor response rate rather than overall survival), trading earlier patient access for a mandatory post-marketing confirmatory trial — failure to complete or a negative confirmatory trial result can lead to accelerated withdrawal, a mechanism that has drawn increasing regulatory and congressional scrutiny in recent years.
Fast Track designation primarily grants rolling review privileges (submitting completed portions of the application before the full dossier is ready) plus more frequent FDA interaction, useful for compressing submission-readiness timelines for serious unmet-need conditions.
These four pathways are not mutually exclusive and are frequently combined — a single novel oncology drug might carry Breakthrough Therapy designation (faster development-stage FDA engagement), Priority Review (shorter formal review clock), and Accelerated Approval (surrogate-endpoint basis) simultaneously, each addressing a different phase of the total time-to-patient timeline.